Maxim Group analyst Jason McCarthy assigned a Buy rating to Adial Pharmaceuticals (ADIL) yesterday and set a price target of $5.00. The company’s shares closed last Wednesday at $2.21.
According to TipRanks.com, McCarthy is a top 25 analyst with an average return of 56.0% and a 61.0% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Appili Therapeutics Inc Class A, Brainstorm Cell Therapeutics, and SELLAS Life Sciences Group.
Currently, the analyst consensus on Adial Pharmaceuticals is a Moderate Buy with an average price target of $5.00.
See today’s analyst top recommended stocks >>
Adial Pharmaceuticals’ market cap is currently $31.81M and has a P/E ratio of -2.80. The company has a Price to Book ratio of 4.63.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Adial Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which is focused on the treatment of alcohol use disorder. Its lead product AD04, a selective serotonin-3 antagonist is in Phase 3 clinical trial. The company was founded by Bankole A. Johnson in November 2010 and is headquartered in Charlottesville, VA.
